Business Context and Reporting Period
Company: Aptevo Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 5, 2020
Reporting Period: Event date November 3, 2020 (Regulation FD Disclosure)
Context: The filing corrects preliminary data regarding the APVO436 Phase 1 clinical trial previously announced in a press release.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding clinical trial data corrections. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes Versus Prior Period
The filing details specific corrections to clinical trial data for a patient in cohort 6 of the APVO436 Phase 1 trial:
- Timing of Complete Remission: Corrected from "after the second cycle" to "by the first day of the fifth cycle" of treatment.
- Bone Marrow Blast Percentages:
- Screening: 29%
- First day of second cycle: 8%
- First day of third cycle: 6% (Corrected from a previous indication of 6% after the first cycle).
- Remission Criteria: Confirmed patient bone marrow blasts at 0.0% with platelet count and absolute neutrophil count meeting complete remission criteria.
Guidance, Outlook, and Risks
Management Commentary: The company issued this report to clarify the timeline and data points of the clinical trial results to ensure accuracy in public disclosures.
Risks and Contingencies: The filing notes that the information is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor subject to the liability of that section, nor incorporated by reference in other filings except as expressly set forth by specific reference.
Important Facts for Investor Verification
- Verify the corrected timeline for the complete remission of the cohort 6 patient (fifth cycle vs. second cycle).
- Confirm the specific bone marrow blast percentage measurements at screening (29%), cycle 2 (8%), and cycle 3 (6%).
- Note that this filing contains no financial data or updated business outlook beyond the clinical data correction.